ORIGINAL ARTICLE



Towards understanding leydigioma: do G protein-coupled estrogen receptor and peroxisome proliferator—activated receptor regulate lipid metabolism and steroidogenesis in Leydig cell tumors?

M. Kotula-Balak ^{1,2} • E. Gorowska-Wojtowicz ¹ • A. Milon ¹ • P. Pawlicki ¹ • W. Tworzydlo ³ • B. J. Płachno ⁴ • I Krakowska ² • A. Hejmej ¹ • J. K. Wolski ⁵ • B. Bilinska ¹

Received: 3 June 2019 / Accepted: 12 February 2020 / Published online: 16 March 2020 © The Author(s) 2020

Abstract

Leydig cell tumors (LCT) are the most common type of testicular stromal tumor. Herein, we investigate the G protein-coupled estrogen receptor (GPER) and peroxisome proliferator–activated receptor (PPAR) implication in regulation of lipid homeostasis including the expression of steroidogenesis-controlling molecules in clinical specimens of LCTs and tumor Leydig cells (MA-10). We showed the general structure and morphology of LCTs by scanning electron and light microscopy. In LCTs, mRNA and protein analyses revealed increased expression of GPER and decreased expression of PPAR α , β , and γ . Concomitantly, changes in expression pattern of the lutropin receptor (LHR), protein kinase A (PKA), perilipin (PLIN), hormone sensitive lipase (HSL), steroidogenic acute regulatory protein (StAR), translocator protein (TSPO), HMG-CoA synthase, and reductase (HMGCS, HMGCR) were observed. Using MA-10 cells treated with GPER and PPAR antagonists (alone and in combination), we demonstrated GPER-PPAR-mediated control of estradiol secretion via GPER-PPAR α and cyclic guanosine monophosphate (cGMP) concentration via GPER-PPAR γ . It is assumed that GPER and PPAR can crosstalk, and this can be altered in LCT, resulting in a perturbed lipid balance and steroidogenesis. In LCTs, the phosphatidylinositol-3-kinase (PI3K)-Akt-mTOR pathway was disturbed. Thus, PI3K-Akt-mTOR with cGMP can play a role in LCT outcome and biology including lipid metabolism.

Keywords G protein-coupled estrogen receptor · Peroxisome proliferator—activated receptor · Leydig cell tumor · Steroidogenesis-controlling molecules · Ultrastructure

Handling Editor: Jörn Bullerdiek

M. Kotula-Balak and E. Gorowska-Wojtowicz have equal contribution.

- M. Kotula-Balak malgorzata.kotula-balak@urk.edu.pl
- Department of Endocrinology, Institute of Zoology and Biomedical Research, Faculty of Biology, Jagiellonian University in Kraków, Poland, Gronostajowa 9, 30-387 Kraków, Poland
- University Centre of Veterinary Medicine, University of Agriculture in Kraków, Mickiewicza 24/28, 30-059 Kraków, Poland
- Department of Developmental Biology and Invertebrate Morphology, Institute of Zoology and Biomedical Research, Faculty of Biology, Jagiellonian University in Kraków, Poland, Gronostajowa 9, 30-387 Kraków, Poland
- Department of Plant Cytology and Embryology, Institute of Botany, Faculty of Biology, Jagiellonian University in Kraków, Poland, Gronostajowa 9, 30-387 Kraków, Poland
- ⁵ nOvum Fertility Clinic, Bociania 13, 02-807 Warszawa, Poland

Introduction

Leydig cell tumor (LCT; leydigioma) is the most common non-germ cell gonadal tumor, accounting for 1-3% of all testicular tumors in adults and 4-9% in prepubertal children (Gheorghisan-Galateanu 2014). In recent years, a marked increase in the incidence of LCTs has been observed (14.7% of all testicular tumors removed). LCTs are usually benign tumors especially in infancy (Bertram et al. 1991), although local recurrence or metachronous tumors of the contralateral testis have also been described. Survival after diagnosis of primary LCTs ranged from 2 months to 17 years (Rich and Keating 2000). In prepubertal patients, even malignant LCTs are less likely to metastasize. Patients with LCTs usually have symptoms of testicular swelling or various endocrinological disruptions (Lai et al. 2015). Gynecomastia is the main clinical manifestation in adults, but it may also be clinically significant in affected children who undergo precocious puberty (Lejeune et al. 1998). Some cases of LCTs were




linked with increased plasma estradiol concentrations (Huang et al. 2013). Moreover, infertility and azoospermia are not an unusual finding in these patients (Bozzini et al. 2017).

Radical orchiectomy is the current standard of care, but testis sparing surgery (TSS) (enucleation), in conjunction with intraoperative frozen section (FSE), has been recently attempted with promising results (Giacaglia et al. 2000). Prepubertal individuals and those with smaller tumors that lack evidence of malignancy are directly recommended for TSS.

The etiology of LCTs is unknown and appears heterogeneous. Furthermore, the molecular basis of LCTs is poorly understood. Some studies showed a possible role of genetic factors in LCT development. Interestingly, genetic mutations identified in children and adults were different and, in some cases, associated with other cancers (Carvajal-Carmona et al. 2006). In adults, it was observed that a somatic activating mutation in the guanine nucleotide-binding protein α gene may result in tumor development, leading to hyperactivity of sex steroid biosynthesis (Bertram et al. 1991). In addition, Carvajal-Carmona et al. (2006) reported an inherited fumarate hydratase mutation appears to cause tumor growth through activation of the hypoxia pathway. According to study of Lejeune et al. (1998), alterations in local stimuli, including Müllerian-inhibiting hormone, inhibin, growth factors, and temperature, may also create favorable conditions for initiation and development of LCTs.

Decreased Leydig cell function is common in men with reproductive disorders, including testicular dysgenesis syndrome (TDS). This syndrome is comprised of subfertility, cryptorchidism, hypospadias, and testicular cancer (Skakkebaek et al. 2001). Leydig cell impairment manifests as a decreased testosterone/lutropin (LH) ratio and the presence of Leydig cell micronodules in the testis (Holm et al. 2003). The number and size of micronodules increase with the severity of TDS (Lardone et al. 2013). Due to ultrastructural changes demonstrated in Leydig cells within micronodules (decreased smooth endoplasmic reticulum, irregularly indented nuclear membrane, decreased lipofuscin pigment granules, and Reinke crystals), failure of their maturation is suggested (Soerensen et al. 2016). In patients with germ cell tumors, Leydig cell hypertrophy and hyperplasia were linked to elevated levels of chorionic gonadotropin (Zimmerli and Hedinger 1991). Various chemicals induced Leydig cell hyperplasia via disruption of the hypothalamicpituitary axis (Dirami et al. 1996). Alternatively, an excess of various hormones (e.g., estrogen, prolactin) produce elevated LH levels that excessively stimulate steroidogenic Leydig cell function (Greaves 2012). Overproliferation of Leydig cells may result in the synthesis of non-functional steroid hormones. Morphologically, no differences appear between spontaneous or chemically induced Leydig cell adenomas (Aoyama et al. 1998). However, there is no evidence as to whether increase of Leydig cell number may further develop into malignant Leydig cell tumor (Gould et al. 2007).



Scarce data are available on the molecular and biochemical characteristics of LCTs. Maintaining an adequate hormonal balance within the testis is the basis for proper gonadal function, thus playing a pivotal role for blocking hormone-secreting Leydig cell tumor development (Seyfried and Shelton 2010).

It is worth noting that biosynthesis of sex steroids is multilevel, controlled process (Miller 2013). It requires the coordinated expression of number of genes, proteins of various function [receptors, e.g., lutropin receptor (LHR), enzymes, transporters, and regulators, e.g., translocator protein (TSPO), steroidogenic acute regulatory protein (StAR)), signaling molecules (e.g., protein kinase A (PKA)], and their regulators in response to LH stimulation. Moreover, for cellular steroidogenic function, global lipid homeostasis is crucial. Perilipin (PLIN), hormone sensitive lipase (HSL), and HMG-CoA synthase (HMGCS) as well as reductase (HMGCR) are members of a cell structural and enzymatic protein machinery controlling lipid homeostasis (Liu et al. 2012). Activation of lipid metabolism is an early event in tumorigenesis (Seyfried and Shelton 2010) however, the precise expression pattern of lipid balance-controlling molecules and their molecular mechanism remains poorly characterized.

This study aims to determine the potential link between GPER and PPAR and whether this interaction regulates lipid homeostasis in LCTs. To further investigate the relationship of Leydig cell tumorigenesis to these receptors while elucidating



the effects of their interactions, mouse tumor Leydig cells (MA-10) were utilized.

Materials and methods

Tissue samples and ethical considerations

Residual tissues from testicular biopsy (microdissection testicular sperm extraction by Schlegel, 1998) were collected at the nOvum Fertility Clinic, Warsaw, Poland from patients (31–45 years old; n = 24) diagnosed due to azoospermia (micronodules LCTs were recognized during surgery). After evaluation by pathologists, patient written informed consent according to the approval regulations by the National Commission of Bioethics at the Jagiellonian University in Krakow, Poland, permit no. 1072.6120.218.2017 and in accordance with the Declaration of Helsinki specimens were used for the present study. Remaining tissue fragments were snap-frozen or fixed and paraffin-embedded and were stored and analyzed at the Department of Endocrinology, Institute of Zoology and Biomedical Research, Jagiellonian University in Krakow, Poland.

Cell culture and treatments

The mouse Leydig cell line MA-10 was a generous gift from Dr. Mario Ascoli (University of Iowa, Iowa City, USA) and was maintained under standard technique (Ascoli 1981). The cells were grown in Waymouth's media (Gibco, Grand Island, NY) supplemented with 12% horse serum and 50 mg/l of gentamicin at 37 °C in 5% $\rm CO_2$. Cells were plated overnight at a density of 1 × 10⁵ cells/mL per well.

Twenty-four hours before the experiments, the medium was removed and replaced with a medium without phenol red supplemented with 5% dextran-coated, charcoal-treated FBS (5% DC-FBS) to exclude estrogenic effects caused by the medium. Next, cells were treated with selective antagonists: GPER $[(3aS^*,4R^*,9bR^*)-4-(6-bromo-1,3-benzodioxol-$ 5-yl)-3a,4,5,9b-3*H*-cyclopenta[*c*]quinolone; G-15] (Tocris Bioscience, Bristol, UK), PPAR α [N-((2S)-2-(((1Z)-1-methyl-3-oxo-3-(4-(trifluoromethyl)phenyl)prop-1-enyl)amino)-3-(4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy)phenyl)propyl)propanamide, GW6471], or PPARy [2-chloro-5-nitro-N-4-pyridinylbenzamide, T0070907] freshly prepared as stock solutions in dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and stored at -20 °C. Stock concentrations were subsequently dissolved in Waymouth's media to a final concentration. Cells were treated with G-15, PPAR α , or PPAR γ alone or together for 24 h. Doses of G-15 (10 nM), PPAR α (10 μM) or PPARγ (10 μM) (Gorowska-Wojtowicz et al. 2018). Control cells were treated with DMSO (final conc. 0.1%). Cell lysates and culture media were frozen in -20 °C for further analyses.

Scanning electron microscopy analysis

LCTs were fixed and processed with the use of Hitachi S-4700 scanning electron microscope (Hitachi, Tokyo, Japan) as previously described (Pawlicki et al. 2019).

Histology

For routine histology, hematoxylin-eosin staining was performed on 4% paraformaldehyde LCT sections. As a control, commercially available paraffin sections of human testis (cat. no. HP-401; Zyagen, San Diego, CA, USA) were used.

RNA isolation, reverse transcription, and real-time quantitative RT-PCR

Total RNA was extracted from LCTs specimens and commercially available normal human Leydig cells (cat. no 10HU-103; ixCells Biotechnologies, San Diego CA, USA) using TRIzol® reagent (Life Technologies, Gaithersburg, MD, USA) according to the manufacturer's instructions. Total cDNA was prepared using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer's instructions. A volume equivalent to 1 μg of total RNA was reverse transcribed. Total cDNA was prepared in a 20- μL volume using a random primer, dNTP mix, RNase inhibitor, and reverse transcriptase (RT). Parallel reactions for each RNA sample were run in the absence of RT to assess genomic DNA contamination. RNase-free water was added in place of the RT product.

RT-PCR was performed using the StepOne Real-Time PCR system (Applied Biosystems) and optimized standard conditions as described previously by Kotula-Balak et al. (2013, 2018b). Based on the gene sequences in Ensembl database, primer sets were designed using Primer3 software (Table 1). Selected primers were synthesized by Institute of Biochemistry and Biophysics, Polish Academy of Sciences (Warsaw, Poland). To calculate the amplification efficiency, serial cDNA dilution curves were produced for all genes. A graph of threshold cycle (Ct) versus log10 relative copy number of the sample from a dilution series was produced. The slope of the curve was used to determine the amplification efficiency: $\%E = (10^{-1/\text{slope}} - 1) \times 100$. All PCR assays displayed efficiency between 94 and 104%. Detection of amplification gene products was performed with 10 ng cDNA, 0.5 µM primers, and SYBR Green master mix (Applied Biosystems) in a final volume of 20 μL. Amplifications were performed as follows: 55 °C for 2 min, 94 °C for 10 min, followed by annealing temperature for 30 s (Table 1), and 45 s 72 °C to determine the cycle threshold (Ct) for quantitative measurement. To confirm amplification specificity, the PCR products from each primer pair were subjected to melting curve analysis and subsequent agarose gel electrophoresis (not



Table 1 Sequences of forward and reverse primers

Genes	Primers (5′–3′)	Product size (bp)	Annealing temperature (°C)	Cycles
GPER	5'-GCCTTGCAGTGGGGATGTCTCATAA-3'	109	59.3	40
	5'-GGATTCAGCTGGTCGATATCACTGGA G-3'			
$PPAR\alpha$	5'-AGCCTCATGAAGAGCCTTCCAACTC-3'	191	59.3	40
$PPAR\beta$	5'-CTGGATTCAGCTGGTCGATATCACTG-3 5'-CACTACGGTGTTCATGCATGTGAGG-3	129	59.3	40
$PPAR\gamma$	5'-GTACTGGCACTTGTTGCGGTTCTTCT-3 5'-GATCAGCTCCGTGGATCTCTCCGTAA3'	207	61.1	40
LHR	5'-GGAGATGCAGGCTCCACTTTGATTG-3' 5'-TGGCCTAGAGTCCATTCAGAGGCTAA-3	304	59.5	40
PKA c.s. α	5'CAGCCAAATCAGGACCCTAAGGAAGT-3' 5'-AACACAAGGAGACCGGGAACCACTAT-3'	140	59.5	40
PLIN 1	5'-CTCGAGTTTGACGAGGAACGGAAAG-3' 5'-CTCCTCCCTCCAGACAAGGAAGAGTC-3'	125	62.7	40
HSL	5'-TATCGAGAGAGGGTGTTGGTCAGAGC-3' 5'-AGCACTACAAACGCAACGAGACAGG-3'	119	59.3	40
StAR	5'-GTTCTGTGTGATCCGCTCAAACTCAG-3' 5'-CTACAGTGACCAGGAGCTGGCCTATC-3'	150	62.7	40
TSPO	5'-CCCACATCTGGGACCACTTTACTCAT-3' 5'-GTACGGCTCCTACCTGGTCTGGAAAG-3'	279	62.7	40
HMGCS1	5'-ACGCAGTAGTTGAGTGTGGTCGTGAA-3' 5'-CTCTTTCACCATGCCTGGATCACTTC-3'	564	59.5	40
HMGCR	5'-GCATTTGGCCCAATTAGCAGAGCTAC-3' 5'GCTCTCCTTCTGGCTGTCAAGTACATC-3'	343	61.3	40
β -actin	5'-CTCCTTTATCACTGCGAACCCTTCAG-3' 5'-AGTTGCGTTACACCCTTTCTTG-3' 5'-CACCTTCACCGTTCCAGTTTT-3'	235	61	40

GPER G-coupled estrogen receptor, $PPAR\alpha$ peroxisome proliferator—activated receptor alpha, $PPAR\beta$ peroxisome proliferator—activated receptor beta, $PPAR\gamma$ peroxisome proliferator—activated receptor gamma, LHR lutropin receptor, PKA c.s. α protein kinase catalytic subunit alpha, PLINI perilipin 1, HSL hormone sensitive lipase, StAR steroidogenic acute regulatory protein, TSPO translocator protein, HMGCS 3-hydroxy-3-methylglutaryl-CoA synthase 1, HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase, β -actin beta-actin

shown). Images were captured using a Bio-Rad Gel Doc XR System (Bio-Rad Laboratories, Hercules, CA, USA) (not shown). mRNA expression within the control group was arbitrarily set as 1, against which statistical significance of experimental groups was analyzed. mRNA expressions were normalized to the β -actin mRNA (relative quantification, RQ = 1) with the use of the $2^{-\Delta\Delta Ct}$ method.

Western blotting

For quantification of protein expression (Table 2), LCT proteins (as a control commercially available normal human Leydig cells; cat. No 10HU-103; ixCells Biotechnologies, San Diego CA, USA) were extracted in radioimmunoprecipitation assay buffer (RIPA; Thermo Scientific, Inc. Rockford IL, USA). Aliquots (50 µg protein) of cell lysates were used for electrophoresis on 12% mini gel by standard SDS-PAGE procedures and electrotransferred to polyvinylidene difluoride (PVDF) membranes (Millipore Corporate, MA, USA) by a semi-dry

transfer cell (Bio-Rad). Then, blots were blocked with 5% non-fat dry milk in TBS, 0.1% Tween 20, overnight at 4 °C with shaking, followed by an incubation with respective antibodies (Table 2).

The membranes were washed and incubated with a secondary antibody conjugated with the horseradish-peroxidase labeled goat anti-mouse or goat anti-rabbit IgGs (Vector Labs., Burlingame, CA, USA) at a dilution 1:1000, for 1 h at RT. Immunoreactive proteins were detected by chemiluminescence with Western Blotting Luminol Reagent (Santa Cruz Biotechnology), and images were captured with a ChemiDoc XRS + System (Bio-Rad Laboratories). All immunoblots were stripped with stripping buffer containing 62.5 mM Tris–HCl, 100 mM 2-mercaptoethanol, and 2% SDS (pH 6.7) at 50 °C for 30 min and incubated in a mouse monoclonal antibody against β -actin. Each data point was normalized against its corresponding β -actin data point.

Quantitative analysis was performed for three separately repeated experiments using a public domain ImageJ software



Table 2 Primary antibodies used for immunohistochemistry and Western blot

Antibody	Host species	Vendor	Dilution
GPER	Rabbit	Abcam	1:50 (IHC)
		cat. no. 39742	1:2000 (WB)
$PPAR\alpha$	Mouse	Thermo Fisher Scientific	1:50 (IHC)
		cat. no. MA1-822	1:1000 (WB)
PPARβ	Rabbit	Thermo Fisher Scientific	1:250 (IHC)
		Cat. No. PA1-823A	1:2000 (WB)
$PPAR\gamma$	Rabbit	Abcam	1:100 (IHC)
		cat. no. 209350	1:4000 (WB)
LHR (H-50)	Rabbit	Santa Cruz Biotechnology	1:20 (IHC)
		cat. no. sc-25,828	1:1000 (WB)
PKAIIα	Rabbit	Santa Cruz Biotechnology	1:200 (IHC)
		cat. no. sc-908	1:5000 (WB)
PLIN-1	Rabbit	Cell Signaling Technology	1:50 (IHC)
		cat. no. 9349	1:2000 (WB)
HSL	Rabbit	Cell Signaling Technology	1:100 (IHC)
		cat. no. 4107	1:1000 (WB)
StAR	Mouse	Abcam	1:100 (IHC)
		cat. no. ab5813	1:1000 (WB)
TSPO	Goat	Thermo Fisher Scientific cat.no. PA5–18565	1:100 (IHC)
			1:1000 (WB)
HMGCS1	Rabbit	Abcam	1:250 (IHC)
		cat. no. ab155787	1:2000 (WB)
HMGCR	Rabbit	Thermo Fisher Scientific	1:50 (IHC)
		cat.no. PA5-18565	1:1000 (WB)
PI3Kp85	Rabbit	Cell Signaling Technology	1:500 (WB)
		cat. no. 4292	
t-Akt	Rabbit	Cell Signaling Technology	1:1000 (WB)
		cat. no. 9272S	
mTOR	Rabbit	Cell Signaling Technology	1:1000 (WB)
β-actin	Mouse	cat. no. 9272S Sigma–Aldrich cat. no. A2228	1:3000 (WB)

GPER G-coupled estrogen receptor, $PPAR\alpha$ peroxisome proliferator-activated receptor alpha, $PPAR\beta$ peroxisome proliferator-activated receptor beta, $PPAR\gamma$ peroxisome proliferator-activated receptor gamma, LHR lutropin receptor, PKA c.s. α protein kinase catalytic subunit alpha, PLINI perilipin 1, HSL hormone sensitive lipase, StAR steroidogenic acute regulatory protein, TSPO translocator protein, HMGCS 3-hydroxy-3-methylglutaryl-CoA synthase 1, HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase, PI3K phosphatidylinositol-45-bisphosphate 3-kinase, t-Akt Akt-serine/threonine-specific protein kinase (protein kinase B), mTOR the mammalian target of rapamycin kinase

(National Institutes of Health, Bethesda, MD) as described elsewhere (Smolen 1999). Protein level within the control group was arbitrarily set as 1, against which statistical significance of experimental groups was analyzed. The relative protein levels were expressed as arbitrary units.

Immunohistochemistry

To optimize immunohistochemical staining testis sections, both commercially available control (Zyagen, San Diego, CA, USA) and LCT sections were immersed in 10 mM citrate

buffer (pH 6.0) and heated in a microwave oven (2 × 5 min, 700 W). After overnight incubation at 4 °C with primary antibodies, (they are listed in Table 2) respective biotinylated antibodies (anti-rabbit and anti-mouse IgGs; 1: 400; Vector, Burlingame CA, USA) and avidin-biotinylated horseradish peroxidase complex (ABC/HRP; 1:100; Dako, Glostrup, Denmark) were applied in succession. Bound antibody was visualized with 3,3'-diaminobenzidine (DAB) (0.05%; v/v; Sigma-Aldrich) as a chromogenic substrate. Control sections included omission of primary antibody and substitution by irrelevant IgG (Bilinska et al. 2018).



cGMP concentration and estradiol secretion

The production of cGMP in control and treated with GPER and PPAR antagonists (alone or in combinations) MA-10 cells was measured by General Cyclic guanosine monophosphate ELISA kit assay (EIAab Wuhan Eiaab Science Co., LTD, Wuhan, China) according to the manufacturer's instructions with detection level 0.31 to 20.0 ng/mL. The cGMP levels were calculated as nanograms per milliliter.

Estradiol Enzyme Immunoassay Kit (DRG, Inc. Int. Springfield, USA) was used for measurement of estradiol content in culture medium from control and treated with GPER and PPAR antagonists (alone or in combinations) MA-10 cells according to the manufacturer's instructions. The sensitivity of the assay was 10.6 pg/mL. The absorbance (λ = 450 nm) was measured. Data were expressed as mean \pm SD.

The measurements were performed with the use ELISA apparatus (Labtech LT-4500).

Statistics


Three biological repeats of each sample (n=7) and three independent experiments were performed. Each variable was tested using the Shapiro-Wilk W test for normality. The homogeneity of variance was assessed with Levene's test. Comparisons were performed by one-way ANOVA, followed by Dunnett's post hoc test (GB-STAT software, v. 7.0; Dynamic Microsystems) to determine the significant differences between proteins expression levels, cGMP content, and estradiol secretion. Statistical analyses were performed on raw data using Statistica 10 software (StatSoft Inc., Tulsa, OK, USA). Data were presented as means \pm S.D. Data were considered statistically significant at *p < 0.05, **p < 0.01, and ***p < 0.001.

Results

Scanning electron microscopic and morphological observations of LCTs

Scanning electron microscopy analyses of LCT biopsy fragments (Fig. 1 A–D) revealed the tumors were relatively compact structures of oval or slightly elongated shape (Fig. 1 A–C) with tumor cells apposed and tightly adhering to one another (Fig. 1 E, F).

It is important to note that some tumor cells were fused. In addition, compact areas of tumor cells were separated by deep grooves. Between those grooves, compact tumor sheets were formed (Fig. 1 E–G). Cells within sheets were compactly linked by thick projections and masses of such connections were observed between cells from neighboring tumor sheets (Fig. 1 E, F). Higher magnification revealed the presence of elongated,



Hematoxylin-eosin staining demonstrated a mixture of four morphological types of cells in the tumor mass when compared to controls, where single or small groups of Leydig cells were seen in the interstitial space (Fig. 2 A, B).

In LCTs, most cells possessed a large polygonal shape with abundant cytoplasm, indistinct cell borders, and regular round to oval nuclei. The nucleus was found to be frequently prominent (Fig. 2 b). Occasionally, cells as those noted above were found to possess distinct cell borders and smaller nuclei (Fig. 2 b'). Small cells with scant, densely eosinophilic cytoplasm and a grooved nucleus (Fig. 2 b'') and spindle-shaped (sarcomatoid) cells (Fig. 2 b''') were observed as well.

Expression and localization of GPER and PPARs in LCTs

In LCTs, increased expression of GPER (p < 0.05) and decreased expression of PPAR α (p < 0.001), PPAR β (p < 0.01), and PPAR γ (p < 0.001) were seen when compared to controls (Fig. 3 a, b). Corresponding to GPER and PPAR protein expressions, changes in their mRNA expressions in LCTs were found (Fig. 3).

No changes in GPER localization and staining intensity were found in control Leydig cells and LCTs (Fig. 4 a, a').

Specifically, the staining was exclusively cytoplasmic and of moderate intensity. Localization and immunostaining intensity of PPAR varied between Leydig cells of control testis and LCTs (Fig. 4 b, b', c, c', d, d'). While strong cytoplasmic-nuclear expression of PPAR α , β , and γ was found in control samples, weak PPAR α immunoexpression and moderate-to-very weak expression of PPAR β and PPAR γ , respectively, were detected. In LCTs, PPARs were located primarily in the cytoplasm of Leydig cells. No positive staining was found when primary antibodies were omitted (Fig. 4, inserts at a, d').

Expression and localization of LHR, PKA, PLIN, HSL, StAR, TSPO, HMGCS, and HMGCR in LCTs

In LCTs, varied expression of LHR, PKA, PLIN, HSL, StAR, TSPO, HMGCS, and HMGCR was observed when compared to normal Leydig cells (Fig. 5 a, b).

The expression of LHR and PKA was increased (p < 0.05 and p < 0.01, respectively) as well as that of HMGCS and HMGCR (p < 0.001 and p < 0.05, respectively). In contrast, PLIN and StAR expressions were decreased (p < 0.001 and p < 0.05, respectively), while a non-significant increase was observed for HSL and TSPO. Changes were also found for mRNA LHR, PKA, PLIN, HSL, StAR, TSPO, HMGCS, and HMGCR expressions in LCTs (Fig. 6).

In control Leydig cells, membrane cytoplasmic and LCT cytoplasmic stainings of LHR were found (Fig. 7 a, a').






Fig. 1 Morphology of human Leydig cell tumors—scanning electron microscopic analysis (**a** A–F and **b** G–L). (A–D) General structure of fragments of testicular biopsies used for analysis. (E, F) Fragments of tissue with tumor. Note solid tumor structure with areas separated by deep grooves. (E, F) and **b** (G, H) cellular masses infiltrating each

other. (I–L) Tumor Leydig cells in mass tightly linked by thick projections formed a cage-like structure covering individual tumor sheets. Representative microphotographs of scanning electron microscopic analysis of human Leydig cell tumors (LCTs). Bars represent 1 μ m. For analysis, n = 12 specimens were used

The immunostaining was of moderate intensity in control Leydig cells but was weak and present in minority of cells of LCTs. No differences were found in PKA distribution and immunostaining (Fig. 7 b, b'), with strong staining present in control and tumor Leydig cell cytoplasm. PLIN distribution, reflecting distribution of lipid droplets, was cytoplasmic in

control Leydig cells and LCTs (Fig. 7 c, c'). In control Leydig cells, staining intensity was strong while found to be weak in LCTs. Increased HSL staining intensity was detected in LCTs when compared to control cells (Fig. 7 d, d') and was exclusively cytoplasmic. Strong immunoreaction was found in the blood vessel epithelium. In contrast, decreased staining




Fig. 2 Morphology of human Leydig cell tumors—hematoxylin-eosin staining representative microphotographs of (A) control human testis and (B, b-b") Leydig cell tumors (LCTs). Scale bars represent 30 μ m. Staining was performed on serial testicular sections from n = 12 specimens. LC - Leydig cells; EC - epithelial cells of blood vessels. (b)— cells of large polygonal shape with abundant, cytoplasm,

indistinct cell borders, and regular, round to oval nuclei (arrows). Prominent nucleus visible at (b) higher magnification (arrowheads), (b')— cells with above features but possessing distinct cell borders and smaller nuclei (arrows), (b")— small cells with scant, densely eosinophilic cytoplasm and grooved nuclei (arrow), (b"")— spindle-shaped (sarcomatoid) cells (arrow)






Fig. 3 Expression of GPER, PPAR α , PPAR β , and PPAR γ in human Leydig cell tumor. (a) Representative immunoblots of qualitative expression of GPER, PPARα, and PPARγ and (b) relative expression (quantitative representation after densitometry of data; arbitrary units). The relative amount of respective proteins normalized to β -actin. Relative intensity from three separate analyses is expressed as means \pm SD. Asterisks show significant differences between respective control and Leydig cell tumor (LCTs). Values are denoted as *p < 0.05,


p < 0.01, and *p < 0.001. Analysis was performed in triplicate (n = 7). (c) Relative level (relative quantification; RO) of mRNA for GPER, PPARα, PPARβ, and PPARγ determined using real-time RT-PCR analysis 2- Δ Ct method. As an intrinsic control, β -actin mRNA level was measured in the samples. RQ from three separate analyses is expressed as means \pm SD. Asterisks show significant differences between respective control and Leydig cell tumor (LCTs). Values are denoted as *p < 0.05 and ***p < 0.001. Analysis was performed in triplicate (n = 7)

intensity of StAR, exclusively present in the cytoplasm (as diffuse signal indicating on distribution of mitochondria), was observed in a few cells of LCTs (Fig. 7 e, e') while control Leydig cells exhibited moderate cytoplasmic staining. A similar pattern was found for mitochondrial TSPO (Fig. 7 f, f'). Moderate, diffused cytoplasmic expression was revealed in control Leydig cell cytoplasm, while the TSPO staining intensity was very weak but still diffused in LCTs. However, in a few cells, immunoreaction was very strong. No differences were found in the distribution of HMGCS and HMGCR between control cells and LCTs (Fig. 7 g, g' and h, h'). Strong cytoplasmic expression of HMGCS and moderate cytoplasmic expression of HMGCR were revealed in control Leydig cells and LCTs, respectively. No positive staining was found when primary antibodies were omitted (Fig. 7, inserts at a, f').

Effect of GPER and PPAR blockage on expression of PI3K, Akt, and mTOR in LCTs and mTOR in MA-10 cells

In LCTs, PI3K and Akt expressions were increased (p < 0.05) while no changes in mTOR expression were found when compared to controls (Fig. 8 a, b).

In MA-10 cells, expression of mTOR was decreased (p < 0.001) after blockage of GPER or GPER together with PPARγ (Fig. 8 c). Blockage of PPARα, PPARγ, or GPER together with PPAR γ increased (p < 0.05, p < 0.01, p < 0.001) mTOR expression.





Effect of GPER and PPAR blockage on estradiol secretion and cGMP concentration in MA-10 cells

Secretion of estradiol markedly increased (p < 0.001) after GPER blockage (Fig. 9 a). A similar increase (p < 0.01) was observed after GPER and PPAR a blockage. Conversely, blockage of GPER and PPAR γ decreased (p < 0.05) estradiol secretion. When either PPAR α or PPAR γ was blocked, no to little alterations (p < 0.05) in hormone secretion were revealed.

Changes in cGMP concentration after antagonist-treatment were similar to those of estradiol secretion (Fig. 9 b). Treatment with a GPER antagonist, alone or in combination with a PPAR α antagonist, increased (p < 0.05, p < 0.01) cGMP concentration while treatment with PPAR α or γ antagonists consistently decreased (p < 0.05) the concentration. Only treatment with GPER and PPARy antagonists in combination increased (p < 0.01) cGMP concentration.

Discussion

Benign LCTs are classically presented as a small (3–5 cm in diameter), sharply delineated, and solid mass embedded within the testis (Al-Agha and Axiotis 2007). Alternatively, malignant LCTs are typically larger (greater than 5 cm in diameter), have infiltrative margins, and show areas of hemorrhage and necrosis. They replace the testis and/or extend beyond testicular parenchyma. For the first time, we showed by scanning electron microscope a complicated LCT cellular organization. We found that




Fig. 4 Localization of GPER, PPAR α , PPAR β , and PPAR γ in human Leydig cell tumor. Representative microphotographs of cellular localization of GPER (a, a' and higher magnification at a'), PPAR α (b, b' and higher magnification at b'), PPAR β (c, c' and higher magnification at c'), and PPAR γ (d, d' and higher magnification at d and d') in control human testes (a–d and higher magnification at d) and Leydig cell tumor (LCTs). DAB immunostaining with hematoxylin counterstaining. Scale bars represent 100 μm. Staining was performed on serial testicular sections from n=12 specimens. Arrows depict cytoplasmic staining; arrowheads depict nuclear staining. No positive staining is seen when the primary antibodies were omitted—insert at a and d' (negative controls)

individual cells were not recognized in the solid mass, but a number of prolongations of various sizes were formed, maintaining cells tightly linked to each other; however, this did not let to distinguish benign and malignant tumors. Morphologically, LCTs can consist predominantly of one type or as a mixture of the four types of cells with abundant lipid accumulation (Richmond et al. 1995). This is in agreement with our observations. In addition, our immunohistochemical results of StAR and PLIN may suggest that LCT cells are overloaded with lipids that probably are not processed to mitochondria.

A central factor in LCT growth and progression is represented by an inadequate intratesticular balance in the androgen/ estrogen ratio with advantage of the latter hormone (Carreau et al. 2010; Fowler et al. 2000; Sirianni et al. 2007). Varying expression patterns of ER α and ER β were observed in human LCTs compared to healthy testis (Carpino et al. 2007). Also, in human and rat LCTs, involvement of GPER in cell proliferation, growth, and apoptosis was shown. Rago et al. (2009, 2011) confirmed the presence of GPER in germ cell tumors and sexcord stromal tumors. However in LCTs, the authors found no differences in GPER expression in relation to normal testis. In contrast, herein, we revealed an increase in GPER expression in LCTs. Also in our in vitro experiments in mouse tumor Leydig cells, GPER expression was increased (Gorowska-Wojtowicz et al. 2018). Taken together, it is likely that various estrogen pathways may be deregulated in LCTs, which reflects tumor heterogeneity and may contribute to its development.

Herein, we showed GPER, alone and together with PPAR α , effected estradiol secretion by tumor Leydig cells. Such result indicates on a leading role of GPER in regulation of sex hormone production and secretion and concomitantly suggests possible GPER and PPAR α alterations in LCTs. Similarly, our prior study also showed progesterone secretion modulation in GPER and PPAR antagonist-treated tumor mouse Leydig cells (Gorowska-Wojtowicz et al. 2018). According to findings by Chimento et al. (2011), GPER is a good target for reduction of tumor Leydig cell proliferation that is hormonally controlled.

We showed, for the first time, a PPAR expression pattern in normal human Leydig cells and its prominent downregulation in LCT. An opposite correlation was found in dog testis, and PPAR expression was always markedly higher in tumor tissue (Sozmen et al. 2013). Notably, confusing results were seen concerning the involvement of PPAR in tumor biology. PPAR was revealed to both promote and inhibit cancer via effects on cell differentiation, growth, metastasis, and lipid metabolism (Maan et al. 2018).

In our findings, both in vivo and in vitro studies revealed possible relationship between GPER, PPAR, and lipid homeostasis-controlling molecules in LCT. Recent studies have linked lipid abundance with increased tumor aggressiveness and its resistance to chemotherapy (Tirinato et al. 2017). Findings by Christian et al. (2013) showed that autophagy influences lipid metabolism via both lipogenesis and lipolysis. Lipid droplets may induce lipophagy to avoid lipotoxicity, a phenomenon caused by excessive lipid accumulation with involvement of the mTOR signaling pathway (Yang et al. 2018). Increased cholesterol content without activated mTOR can be






Fig. 5 Expression of LHR, PKA, PLIN, HSL, StAR, TSPO, HMGCS, and HMGCR in human Leydig cell tumor. (a) Representative blots of qualitative expression of LHR, PKA, PLIN, HSL, PLIN, StAR, TSPO, HMGCS, and HMGCR and (b) relative expression (quantitative representation after densitometry of data; arbitrary units). The relative

amount of respective proteins normalized to β -actin. Relative intensity from three separate analyses is expressed as means \pm SD. Asterisks show significant differences between respective control and Leydig cell tumor (LCTs). Values are denoted as *p<0.05, **p<0.01, and ***p<0.001. Analysis was performed in triplicate (n=7)




Fig. 6 Expression of mRNA for *LHR*, *PKA*, *PLIN*, *HSL*, *StAR*, *TSPO*, *HMGCS*, and *HMGCR* in human Leydig cell tumor. Relative level (relative quantification; RQ) of mRNA for *LHR*, *PKA*, *PLIN*, *HSL*, *PLIN*, *StAR*, *TSPO*, *HMGCS*, and *HMGCR* determined using real-time RT-PCR analysis $2-\Delta$ Ct method. As an intrinsic control, β -actin mRNA

level was measured in the samples. RQ from three separate analyses is expressed as means \pm SD. Asterisks show significant differences between respective control and Leydig cell tumor (LCTs). Values are denoted as *p < 0.05, **p < 0.01, and ***p < 0.001. Analysis was performed in triplicate (n = 7)






Fig. 7 Localization of LHR, PKA, PLIN, HSL, StAR, TSPO, HMGCS, and HMGCR in human Leydig cell tumor. Representative microphotographs of cellular localization of LHR (a–a'), PKA (b–b'), PLIN (c–c' and higher magnifications at c and c'), HSL (d–d'), StAR (e–e'), TSPO (f–f'), HMGCS (g–g'), and HMGCR (h–h') in control human testes (a–h and higher magnification at c) and Leydig cell tumor (a'–h' and higher magnification at c'). DAB immunostaining with

hematoxylin counterstaining. Scale bars represent $100 \mu m$. Staining was performed on serial testicular sections from n = 12 specimens. Arrows depict cytoplasmic staining. Arrowheads depict strong stained cells for TSPO and positively stained epithelial cells of blood vessels for HSL. No positive staining is seen when the primary antibodies were omitted—insert at a and f (negative controls)

an indirect result of lipophagy and/or PLIN alterations in LCTs. It seems this particular tumor can have a distinct biology, but it is possible that some mechanisms may be induced later when its development is more advanced. Last data demonstrate that lipophagy contributes to testosterone biosynthesis at least partially through degrading lipid droplets and cholesterol content (Ma et al. 2018). In steroidogenic cells, the mechanism underlying lipid turnover and receptor involvement remained unrevealed (Maizlin et al. 2004); however, based on our results, GPER-PPAR cross-talk should be taken into consideration.

We found prominent changes in LHR, StAR, and PKA expressions, reflecting disturbances in lipid controlling mechanisms directly associated with central endocrine regulation and the local microenvironment. In LCT, we detected decreased expression of StAR and increased expression of LHR. In contrary, in tumor mouse Leydig cell line (mLTC-1), StAR activity was increased while LHR expression was significantly reduced (Manna et al. 2007). These discrepancies may be due to species specific characteristics of tumor Leydig cells or may be ascribed to abovementioned tumor heterogeneity or complex mechanisms regulating protein biology (Bauer et al. 2015). Nevertheless, the






Fig. 8 Expression of PI3K-Akt-mTOR pathway in human Leydig cell tumor. (a) Representative blots of qualitative expression of PI3K, Akt, mTOR, and (b) relative expression (quantitative representative after densitometry of data; arbitrary units). The relative amount of respective proteins normalized to β-actin. Relative intensity from three separate analyses is expressed as means \pm SD. Asterisks show significant differences between control and Leydig cell tumor (LCTs). Values are denoted as *p<0.05. Analysis was performed in triplicate (n = 7). (c) Effect of GPER

and PPAR blockage on expression of mTOR in MA-10 cells. Representative blots of qualitative expression of mTOR and relative expression (quantitative representation after densitometry of data; arbitrary units). The relative amount of protein normalized to β -actin. Relative intensity from three separate analyses is expressed as means \pm SD. Asterisks show significant differences between control and treated Leydig cells. Values are denoted as *p < 0.05, **p < 0.01, and ***p < 0.001. Analysis was performed in triplicate (n = 3 for each experimental group)

regulation of steroidogenesis is clearly disturbed in LCT. Moreover, in our study, LHR was found in the cytoplasm as this receptor can be internalized. Internalization is a part of the physiological mechanism of action for many G-coupled receptors in a specific condition, e.g., agonist treatment, influence of tissue/cell microenvironment (Reubi 2014). In pathological conditions, translocation of proteins is usually observed phenomenon.

Perturbations in StAR expression patterns observed in the present study may reflect altered mitochondrial function and/or degradation (mitophagy), thus affecting lipid homoeostasis in TLCs (Barbosa and Siniossoglou 2017). Herein, HSL and TSPO expressions did not vary in LCTs, suggesting a subordinate role of these molecules in LCTs.





Fig. 9 Effect of GPER and PPAR blockage on expression on estradiol secretion and cGMP concentration in MA-10 cells. Estradiol secretion (a) and cGMP concentration (b) in control and treated with GPER (10 nM), PPAR α (10 μ M) and PPAR γ (μ M) antagonists alone or in combinations



for 24 h tumor mouse Leydig cells (MA-10). Asterisks show significant differences between control and treated Leydig cells. Values are denoted as *p < 0.05, **p < 0.01, and ***p < 0.001. Analysis was performed in triplicate (n = 3 for each experimental group)



Lipid droplet associated proteins are actively involved in modulating lipid homeostasis by generating sites for steroidogenic enzyme activity (Shen et al. 2016). Changes in PLIN expression found in our study may suggest that in LCT not only transport of cholesterol to mitochondria but also lipid storage and mobilization from lipid droplets are dysregulated. This may be considered as additional factor aiding in the development of LCTs.

Enhanced expression of sterol regulatory element binding proteins (SREBPs), involved in cholesterol and fatty acids synthesis through the Akt pathway (anchored-lipid membrane protein), correlates with tumor development, progression, and invasiveness, as well as increased lipid content in cell membranes (Beloribi-Djefaflia et al. 2016). Through both the post-translational regulation and induction of transcriptional programs, the dysregulated PI3K-Akt-mTOR pathway coordinates the uptake and utilization of multiple nutrient lipids supporting the enhanced growth and proliferation of cancer cells (Basharat et al. 2016). In this study, we found PI3K, Akt, and mTOR signaling alterations, which indicate that also LCT deregulation of these pathways may be an important event accompanying tumor development. Notably, changes in hormonal milieu including estradiol can result in modulation and mTOR activity (Blagosklonny 2010). Our earlier studies in mouse tumor Leydig cells revealed that GPER and PPAR inhibitions activated PI3K and Akt (Gorowska-Wojtowicz et al. 2018). Here we showed that in addition, mTOR was modulated diversely dependently on receptor antagonist used alone or in combination, inhibited by GPER antagonist alone and together with PPARy antagonist as well as activated by GPER with PPAR α together and the latter alone. Therefore, these results demonstrated that GPER- and PPARα-mediated pathways are involved in the maintenance of mTOR activity, whereas PPARy signaling has an opposite effect, reducing mTOR activity.

Distinct changes in cGMP level suggest GPER-PPAR-mediated high or only via PPAR low metastatic activity of LCT. cGMP agonist was confirmed as a mediator of lipolysis in oocytes (Mendoza et al. 2011). In LCTs, cGMP seems to be important in maintaining lipid homeostasis when GPER and PPAR are absent.

The outcome of lipid content modification is a result of various protein–protein cross-talk that was revealed here also between GPER-PPAR and HMGCS and HMGCR resulting in overexpression of the latter enzymes that is in line with our earlier in vitro study (Gorowska-Wojtowicz et al. 2018). HMGCS/HMGCR implications in cancer cell proliferation and cooperation with Ras signaling are currently used in cholesterol-lowering drug therapy (Schwarz et al. 2018). According to Ding et al. (2008), HMGCR is an important marker for tumor testis transformation in mice.

Conclusion

Mechanisms concerning Leydig cell tumorigenesis are scarcely known, and the role of lipid metabolism in tumor cells has long been disregarded. Very recently, it was suggested that knowing reprogramming of metabolic mechanisms in tumor can be used as prominent future target of therapy (Sreedhar and Zhao 2018). We presented here, for the first time, alterations in lipid- and cholesterol-associated proteins and one possible mechanisms of action of these molecules in LCT, which concomitantly may be primary disturbances in healthy Leydig cell. Further studies are needed to elucidate the type, role, and regulation of lipids synthesized in tumors of steroidogenic cells. Our findings shed light on the novel functional interplay between GPER and PPAR ultimately probably controlling and/or affecting lipid metabolism and steroidogenesis in LCTs. Modifications of expression of LHR, PKA, PLIN, HSL, StAR, TSPO, HMGCS, and HMGCR, together with cGMP and PI3K-Akt-mTOR pathways, may be suitable in developing innovating approaches (combined with transcriptome/proteome analyses and lipidomic data) that target pathological processes of Leydig cells. There is an urgent need for additional experimental and clinical data to complete the current knowledge on the biology and molecular characteristics of LCTs that will guide the early diagnostics, treatment, and surveillance of incoming patients with this disease. Another important issue is elaboration of experimental model that we are currently working on (Gorowska-Wojtowicz et al. 2019) including those more accurately reflecting human tumor, e.g., human tumor Leydig cell lines and human tumor xenografts.

Acknowledgments The authors are grateful to Grzegorz Kapuscinski, FEBU (urologist) and Robert Wyban, MS (LAB-IVF) (nOvum Fertility Clinic, Warszawa) for cooperation. We thank Miss Maja Kudrycka and Miss Patrycja Dutka (Department of Endocrinology) for technical help in qRT-PCR and Western blotting analyses. The authors are very much grateful to editor and anonymous reviewers for their constructive suggestions and helpful comments that allow improve this manuscript.

Financial information This work was supported by a grant OPUS12 2016/23/B/NZ4/01788 from National Science Centre, Poland.

Author contributions Authors' contribution to the work described in the paper: M.K-B., E.G-W., A.M., P.P., W.T., B.J. P., I.K., and A.H. performed research. J.K.W employed in nOvum Fertility Clinic, Warszawa, Poland collected clinical samples. M.K-B., E.G-W., W.T., A.H., and J.K. W. analyzed the data. B.B. critically reviewed the manuscript. M.K.-B. designed the research study and wrote the paper. All authors have read and approved the final version of the manuscript.

Compliance with ethical standards

After evaluation by pathologists, patient written informed consent according to the approval regulations by the National Commission of Bioethics at the Jagiellonian University in Krakow, Poland, permit no. 1072.6120.218.2017 and in accordance with the Declaration of Helsinki remaining specimens were used for the present study.



Conflict of interest The authors declare that they have no conflict of interest

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

- Al-Agha OM, Axiotis CA (2007) An in-depth look at Leydig cell tumor of the testis. Arch Pathol Lab Med 131:311–317
- Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzales FJ (1998) Altered constitutive expression of fatty acidmetabolizing enzymes in mice lacking the peroxisome proliferatoractivated receptor alpha (PPARalpha). J Biol Chem 273:5678–5684
- Ascoli M (1981) Characterization of several clonal lines of cultured Leydig tumor cells: gonadotropin receptors and steroidogenic responses. Endocrinology 108:88–95
- Barbosa AD, Siniossoglou S (2017) Function of lipid droplet-organelle interactions in lipid homeostasis. Biochim Biophys Acta 1864: 1459–1468
- Basharat P, Arash H, Lahouti AH, Paik JJ, Albayda J, Pinal-Fernandez I, Bichile T, Lloyd TE, Danoff SK, Casciola-Rosen L, Mammen AL, Christopher-Stine L (2016) Statin-induced anti-HMGCR-associated myopathy. J Am Coll Cardiol 68:234–235
- Bauer NC, Doetsch PW, Corbett AH (2015) Mechanisms regulating protein localization. Traffic 16:1039–1061
- Beloribi-Djefaflia S, Vasseur S, Guillaumond F (2016) Lipid metabolic reprogramming in cancer cells. Oncogenesis 25:e189
- Bertram KA, Bratloff B, Hodges GF, Davidson H (1991) Treatment of malignant Leydig cell tumor. Cancer 68:2324–2329
- Bilinska B, Hejmej A, Kotula-Balak M (2018) Preparation of testicular samples for histology and immunohistochemistry. In: Alves M, Oliveira P (eds) Sertoli cells, methods in molecular biology, vol 1748. Humana Press, New York
- Blagosklonny MV (2010) Increasing healthy lifespan by suppressing aging in our lifetime: preliminary proposal. Cell Cycle 24:4788– 4794
- Bozzini G, Ratti D, Carmignani L, en representación de Young Academic Urologists (YAU) Men's Health Group (2017) Treatment of leydig cell tumours of the testis: can testis-sparing surgery replace radical orchidectomy? Results of a systematic review. Actas Urol Esp 41: 146–154
- Braissant O, Foufelle F, Scotto C, Dauça M, Wahli W (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137:354–366
- Carpino A, Rago V, Pezzi V, Carani C, Andò S (2007) Detection of aromatase and estrogen receptors (ERalpha, ERbeta1, ERbeta2) in human Leydig cell tumor. Eur J Endocrinol 2:239–244
- Carreau S, Wolczynski S, Galeraud-Denis I (2010) Aromatase, oestrogens and human male reproduction. Philos Trans R Soc Lond Ser B Biol Sci 365:1571–1579

- Carvajal-Carmona LG, Alam NA, Pollard PJ, Jones AM, Barclay E, Wortham N, Pignatelli M, Freeman A, Pomplun S, Ellis I, Poulsom R, El-Bahrawy MA, Berney DM, Tomlinson IP (2006) Adult leydig cell tumors of the testis caused by germline fumarate hydratase mutations. J Clin Endocrinol Metab 91:3071–3075
- Chimento A, Casaburi I, Bartucci M, Patrizii M, Dattilo R, Avena P, Andò S, Pezzi V, Sirianni R (2011) Selective GPER activation decreases proliferation and activates apoptosis in tumor Leydig cells. Cell Death Dis 1:e747
- Chimento A, Sirianni R, Casaburi I, Pezzi V (2014) GPER signaling in spermatogenesis and testicular tumors. Front Endocrinol (Lausanne) 6:30
- Christian P, Sacco J, Adeli K (2013) Autophagy: emerging roles in lipid homeostasis and metabolic control. Biochim Biophys Acta 1831: 819–874
- Ding J, Jiang D, Kurczy M, Nalepka J, Dudley B, Merkel EI, Porter FD, Ewing AG, Winograd N, Burgess J, Molyneaux K (2008) Inhibition of HMG CoA reductase reveals an unexpected role for cholesterol during PGC migration in the mouse. BMC Dev Biol 31:120
- Dirami G, Teerds KJ, Cooke BA (1996) Effect of a dopamine agonist on the development of Leydig cell hyperplasia in Sprague-Dawley rats. Toxicol Appl Pharmacol 141:169–177
- Fietz D, Ratzenböck C, Hartmann K, Raabe O, Kliesch S, Weidner W, Klug J, Bergmann M (2014) Expression pattern of estrogen receptors α and β and G-protein-coupled estrogen receptor 1 in the human testis. Histochem Cell Biol 142:421–432
- Fietz D, Bergmann M, Hartmann K (2016) In situ hybridization of estrogen receptors α and β and GPER in the human testis. Methods Mol Biol 1366:189–205
- Fowler KA, Gill K, Kirma N, Dillehay DL, Tekmal RR (2000) Overexpression of aromatase leads to development of testicular Leydig cell tumors: an in vivo model for hormone-mediated testicular cancer. Am J Pathol 156:347–353
- Gheorghisan-Galateanu AA (2014) Leydig cell tumors of the testis: a case report. BMC Res Notes 7:656
- Giacaglia LR, Kohek MB d F, Carvalho FM, Fragoso MC, Mendonca B, Latronico AC (2000) No evidence of somatic activating mutations on gonadotropin receptor genes in sex cord stromal tumors. Fertil Steril 74:992–995
- Gorowska-Wojtowicz E, Dutka P, Kudrycka M, Pawlicki P, Milon A, Plachno BJ, Tworzydlo W, Pardyak L, Kaminska A, Hejmej A, Bilinska B, Kotula-Balak M (2018) Regulation of steroidogenic function of mouse Leydig cells: G-coupled membrane estrogen receptor and peroxisome proliferator-activated receptor partnership. J Physiol Pharmacol 69(3). https://doi.org/10.26402/jpp.2018.3.04
- Gorowska-Wojtowicz E, Duliban M, Kudrycka M, Dutka P, Pawlicki P, Milon A, Zarzycka M, Placha W, Kotula-Balak M, Ptak A, Wolski JK, Bilinska B (2019) Leydig cell tumorigenesis implication of G-coupled estrogen receptor/peroxisome proliferator-activated receptor interaction and xenoestrogen exposure. In vivo and in vitro appraisal. Tissue Cell 61:51–60
- Gould ML, Hurst PR, Nicholson HD (2007) The effects of oestrogen receptors alpha and beta on testicular cell number and steroidogenesis in mice. Reproduction 134:271–279
- Greaves P (2012) Histopathology of preclinical toxicity studies: interpretation and relevance in drug safety evaluation, 4th edn. Elsevier AP, Amsterdam
- Harada Y, Tanaka N, Ichikawa M, Kamijo Y, Sugiyama E, Gonzalez FJ, Aoyama T (2016) PPARα-dependent cholesterol/testosterone disruption in Leydig cells mediates 2,4-dichlorophenoxyacetic acidinduced testicular toxicity in mice. Arch Toxicol 90:3061–3071
- Hess RA (2003) Estrogen in the adult male reproductive tract: a review. Reprod Biol Endocrinol 1:52
- Holm M, Rajpert-De Meyts E, Andersson AM, Skakkebaek NE (2003) Leydig cell micronodules are a common finding in testicular



- biopsies from men with impaired spermatogenesis and are associated with decreased testosterone/LH ratio. J Pathol 199:378–386
- Huang Y, Song J, Xu M, Zan Q (2013) Primary Leydig cell tumour of epididymis: a rare case report with review of literature. Andrologia 45:430–433
- Kotula-Balak M, Hejmej A, Kopera I, Lydka M, Bilinska B (2012) Prenatal and neonatal exposure to flutamide affects function of Leydig cells in adult boar. Domest Anim Endocrinol 42:142–154
- Kotula-Balak M, Chojnacka K, Hejmej A, Galas J, Satola M, Bilinska B (2013) Does 4-tert-octylphenol affect estrogen signaling pathways in bank vole Leydig cells and tumor mouse Leydig cells in vitro? Reprod Toxicol 39:6–16
- Kotula-Balak M, Milon A, Pawlicki P, Opydo-Chanek M, Galas J, Pacwa A, Lesniak K, Sekula M, Bilinska B, Zarzycka M, Tworzydlo W, Bubka M, Hejmej A (2018a) Diverse role of estrogen-related receptors α, β and γ in biology of tumor Leydig cell. Tissue Cell 52:78–91
- Kotula-Balak M, Chojnacka K, Hejmej A, Galas J, Satola M, Bilinska B (2013) Does 4-tert-octylphenol affect estrogen signaling pathways in bank vole Leydig cells and tumor mouse Leydig cells in vitro? Reprod Toxicol 39:6–16
- Kotula-Balak M, Milon A, Pawlicki P, Opydo-Chanek M, Galas J, Pacwa A, Lesniak K, Sekula M, Bilinska B, Zarzycka M, Tworzydlo W, Bubka M, Hejmej A (2018a) Diverse role of estrogen-related receptors α , β and γ in biology of tumor Leydig cell. Tissue Cell 52:78–91
- Kotula-Balak M, Pawlicki P, Milon A, Tworzydlo W, Sekula M, Pacwa A, Gorowska-Wojtowicz E, Bilinska B, Pawlicka B, Wiater J, Zarzycka M, Galas J (2018b) The role of G-protein-coupled membrane estrogen receptor in mouse Leydig cell function-in vivo and in vitro evaluation. Cell Tissue Res 374:389–412. https://doi.org/10.1007/s00441-018-2861-7
- Lai N, Zeng X, Li M, Shu J (2015) Leydig cell tumor with lung metastasis diagnosed by lung biopsy. Int J Clin Exp Pathol 8:12972–12976
- Lardone MC, Piottante A, Valdevenito R, Ebensperger M, Castro A (2013) Histological and hormonal testicular function in oligo/azoospermic infertile men. Andrologia 45:379–385
- Lejeune H, Habert R, Saez JM (1998) Origin, proliferation and differentiation of Leydig cells. J Mol Endocrinol 20:1–25
- Levin ER (2011) Minireview: extranuclear steroid receptors: roles in modulation of cell functions. Mol Endocrinol 25:377–384
- Liu TF, Tang JJ, Li PS, Shen Y, Li JG, Miao HH, Li BL, Song BL (2012) Ablation of gp78 in liver improves hyperlipidemia and insulin resistance by inhibiting SREBP to decrease lipid biosynthesis. Cell Metab 8:213–225
- Ma Y, Zhou Y, Zhu YC, Wang SQ, Ping P, Chen XF (2018) Lipophagy contributes to testosterone biosynthesis in male rat Leydig cells. Endocrinology 2:1119–1129
- Maan M, Peters JM, Dutta M, Patterson AD (2018) Lipid metabolism and lipophagy in cancer. Biochem Biophys Res Commun 10:S0006-291X(18)30326-7
- Maizlin ZV, Belenky A, Kunichezky M, Sandbank J, Strauss S (2004) Leydig cell tumors of the testis: gray scale and color Doppler sonographic appearance. J Ultrasound Med 23:959–964
- Manna PR, Jo Y, Stocco DM (2007) Regulation of Leydig cell steroidogenesis by extracellular signal-regulated kinase 1/2: role of protein kinase A and protein kinase C signaling. J Endocrinol 193:53–63
- Mendoza MC, Er EE, Blenis J (2011) The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36: 320–328
- Miller WL (2013) A brief history of adrenal research: steroidogenesis the soul of the adrenal. Mol Cell Endocrinol 22:5–14
- Pawlicki P, Hejmej A, Milon A, Lustofin K, Płachno BJ, Tworzydlo W, Gorowska-Wojtowicz E, Pawlicka B, Kotula-Balak M, Bilinska B (2019) Telocytes in the mouse testicular interstitium. Implications of G-protein coupled estrogen receptor (GPER) and estrogen related receptor (ERR) in regulation of mouse testicular interstitial cells. Protoplasma 256:393–408

- Prossnitz ER, Barton M (2011) The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol 12:715–726
- Rago V, Romeo F, Giordano F, Ferraro A, Ando S, Carpino A (2009) Identification of ERbeta1 and ERbeta2 in human seminoma, in embryonal carcinoma and in their adjacent intratubular germ cell neoplasia. Reprod Biol Endocrinol 7:56. https://doi.org/10.1186/1477-7827-7-56
- Rago V, Romeo F, Giordano F, Maggiolini M, Carpino A (2011) Identification of the estrogen receptor GPER in neoplastic and non-neoplastic human testes. Reprod Biol Endocrinol 9:135. https://doi.org/10.1186/1477-7827-9-135
- Reubi JC (2014) Strict rules are needed for validation of G-proteincoupled receptor immunohistochemical studies in human tissues. Endocrine 47:659–661
- Rich MA, Keating MA (2000) Leydig cell tumors and tumors associated with congenital adrenal hyperplasia. Urol Clin North Am 27:519– 528
- Richmond I, Banerjee SS, Eyden BP, Sissons MC (1995) Sarcomatoid Leydig cell tumor of the testis. Histopathology 27:578–580
- Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA (1992) Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol 6:1634–1641
- Schwarz KRL, de Castro FC, Schefer L, Botigelli RC, Paschoal DM, Fernandes H, Leal CLV (2018) The role of cGMP as a mediator of lipolysis in bovine oocytes and its effects on embryo development and cryopreservation. PLoS One 13:e0191023
- Seyfried TN, Shelton LM (2010) Cancer as a metabolic disease. Nutr Metab 27:7
- Shen WJ, Azhar S, Kraemer FB (2016) Lipid droplets and steroidogenic cells. Exp Cell Res 15:209–214
- Sirianni R, Chimento A, Malivindi R, Mazzitelli I, Andò S, Pezzi V (2007) Insulin-like growth factor-I, regulating aromatase expression through steroidogenic factor 1, supports estrogen-dependent tumor Leydig cell proliferation. Cancer Res 67:8368–8377
- Skakkebaek NE, Rajpert-De Meyts E, Main KM (2001) Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 5:972–978
- Smolen AJ (1999) In: Conn PM (ed) Image analytic techniques for quantification of immunocytochemical staining in the nervous system. Methods Neurosci Acad Press, San Diego
- Soerensen RR, Johannsen TH, Skakkebaek NE, Rajpert-De Meyts E (2016) Leydig cell clustering and Reinke crystal distribution in relation to hormonal function in adult patients with testicular dysgenesis syndrome (TDS) including cryptorchidism. Hormones (Athens) 15:518–526
- Sozmen M, Kabak YB, Gulbahar MY, Gacar A, Karayigit MO, Guvenc T, Yarim M (2013) Immunohistochemical characterization of peroxisome proliferator-activated receptors in canine normal testis and testicular tumours. J Comp Pathol 149:10–18
- Sreedhar A, Zhao Y (2018) Dysregulated metabolic enzymes and metabolic reprogramming in cancer cells. Biomed Rep 8:3–10
- Tazi MF, Mellas S, El Fassi MJ, Farih MH (2008) Leydig cell hyperplasia revealed by gynecomastia. Rev Urol 10:164–167
- Tirinato L, Pagliari F, Limongi T, Marini M, Falqui A, Seco J, Candeloro P, Liberale C, Di Fabrizio E (2017) An overview of lipid droplets in cancer and cancer stem. Cells Stem Cells Int 2017:1656053
- Yang M, Zhang Y, Ren J (2018) Autophagic regulation of lipid homeostasis in cardiometabolic syndrome. Front Cardiovasc Med 3:38
- Zimmerli UU, Hedinger CE (1991) Hyperplasia and hypertrophy of Leydig cells associated with testicular germ cell tumours containing syncytiotrophoblastic giant cells. Virchows Arch A Pathol Anat Histopathol 419:469–474

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

